Lonza Group AG
LONN
Rangering i aksjer
#447
Lonza Group AG, together with its subsidiaries, operates as a contract... Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Aksjekurs
$766.95
Markedsverdi
$53.57B
Endring (1 dag)
1.35%
Endring (1 år)
9.01%
Land
CH
Handel Lonza Group AG (LONN)
Kategori
Healthcare
Historikk for aksjesplitt for Lonza Group AG (LONN)
Aksjen Lonza Group AG (symbol: LONN) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 22, 2026.
Én LONN-aksje kjøpt før Oct 22, 2026 tilsvarer i dag 0 LONN-aksjer.
Den nyeste splittelsen skjedde Oct 22, 2026.
Én LONN-aksje kjøpt før Oct 22, 2026 tilsvarer i dag 0 LONN-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 1 | x100 |
BE
|
